1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Medico Remedies Ltd.

Medico Remedies Ltd.

20.50
INR
-0.28
(-1.35%)
1.67EPS
23.15P/E
3.20BMarket Cap
Medico Remedies Ltd.
NSE:MEDICO
(National Stock Exchange of India)

Recent

price

20.50

P/E

ratio

23.15

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
4.07
5.41
6.14
8.04
6.56
9.12
11.77
10.68
14.44
14.26
16.69
17.27
17.91
24.59
28.68
Revenue per Share
0.05
0.08
0.1
0.14
0.2
0.18
0.19
0.2
0.31
0.58
0.87
1
1.22
1.58
1.67
Basic EPS, GAAP
0.03
-0.18
-0.29
-0.49
-0.49
0.64
0.15
-0.28
-3.41
-0.01
0.19
- -
0.21
0.17
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.61
1.03
1.64
1.78
1.97
3.21
3.4
3.6
3.83
4.41
5.28
6.31
7.53
9.1
- -
Book Value per Share
0.61
1.03
1.64
1.78
1.97
3.21
3.4
3.6
3.83
4.41
5.27
6.3
7.52
9.09
- -
Tangible Book Value per Share
83
83
83
83
83
67
83
83
83
83
83
83
83
83
83
Basic Weighted Avg Shares
337
449
510
667
544
610
977
886
1,198
1,183
1,385
1,433
1,487
2,041
2,375
Sales/Revenue/Turnover
3.11
3.24
3.24
3.93
5.72
4.06
1.28
1.33
4.64
4.49
4.98
7
8.05
6.83
6.08
Operating Margin (%)
4
7
13
12
11
10
15
17
17
44
54
29
30
31
30
Depreciation Expense
4
6
8
11
16
12
16
16
26
48
72
83
101
131
138
Net Income, GAAP
39.4
34.33
28.08
39.62
3.56
34.84
27.81
26.4
30
25.78
28.29
26.86
25.26
27.38
27.16
Effective Tax Rate (%)
1.27
1.4
1.55
1.69
2.99
2
1.61
1.84
2.16
4.07
5.23
5.79
6.79
6.43
5.82
Profit Margin (%)
10
14
47
104
170
155
137
162
198
194
228
309
397
513
- -
Working Capital
- -
- -
- -
37
108
22
24
47
50
26
13
9
4
3
- -
LT Debt
51
86
136
147
164
267
282
299
318
366
438
524
625
755
- -
Total Equity
- -
6.91
6.77
6.32
8.43
4.3
2.23
2.03
5.58
7.99
9.65
12.81
12.67
11.24
- -
Return on Invested Capital (%)
- -
7.47
7.2
6.56
8.33
5.33
5.06
5.25
6.94
10.8
14.9
15.37
15.6
16.09
- -
Return on Capital (%)
- -
9.23
7.14
7.97
10.47
5.67
5.72
5.61
8.4
14.07
18.01
17.23
17.58
19.02
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
190
- -
LT Borrowings
- -
3
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
83
83
83
Market Capitalization
4,199
2,719
3,204

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,289
- -
Cash, Cash Equivalents & STI
- -
38
- -
Accounts Receivable, Net
- -
820
- -
Inventories
- -
300
- -
Total Current Liabilities
- -
776
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
190
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
18.87%
20.82%
Free Cash Flow
-722.8%
-1,551.97%
-18.79%
Net Income, GAAP
31.29%
40.49%
29.94%
Sales/Revenue/Turnover
14%
12.05%
37.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
308
393
395
413
1,487
2026
383
526
587
568
2,041
2027
694
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.19
0.19
0.32
0.52
1.22
2026
0.22
0.31
0.35
0.71
1.58
2027
0.3
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Medico Remedies Limited (MEDICO.NS), a pharmaceutical formulation manufacturing and marketing company, develops, manufactures and sells a broad range of generic medicines including tablets, capsules, dry syrups, ointments, creams and injectables with a focus on anti-infectives, beta-lactams, cephalosporins, antimalarials, antiretrovirals, anti-ulcer drugs, antacids, vitamins, haematinics and supplements; NSAIDS, antihistaminics, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, antidepressants, antipsychotics, antifungals, antiparasitics and combination drug kits for various therapeutic segments. Incorporated in 1994 and headquartered in Palghar, Maharashtra, India, with registered office in Mumbai, the company operates manufacturing facilities certified under WHO-GMP and ISO-9001:2015 standards, serving domestic clients such as Directorate of Health Services Maharashtra and international customers including Anphar Limited, Saad Medical and Award Global Company Limited across markets in the Dominican Republic, Turkmenistan and other regions. Recent developments include securing a government supply order worth USD 1.78 million (Rs 15 crore approx.) from Turkmenistan's Main Pharmacy Association of the Ministry of Health in October 2025 for tablets, capsules and dry syrups; an earlier Rs 16.31 crore order from Dominican Republic's PROMESE/CAL in April 2025 for similar products; alongside robust financial performance with Q3 FY25 net profit rising 80.7% to Rs 2.62 crore on 32.7% sales growth to Rs 39.49 crore and June 2025 quarter sales up 24.2% to Rs 38.25 crore.